دورية أكاديمية
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
| العنوان: | Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib |
|---|---|
| المؤلفون: | Castagnetti, F, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, ALBANO, FRANCESCO, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M. |
| المساهمون: | Castagnetti, F, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, Albano, Francesco, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M. |
| سنة النشر: | 2015 |
| المجموعة: | Università degli Studi di Bari Aldo Moro: CINECA IRIS |
| مصطلحات موضوعية: | DIAGNOSED CHRONIC-PHASE, CHRONIC MYELOGENOUS LEUKEMIA, PATIENTS RECEIVING IMATINIB, BCR-ABL1 TRANSCRIPT LEVELS, EARLY MOLECULAR RESPONSE, FOLLOW-UP, 400 MG, CYTOGENETIC RESPONSE, 1ST-LINE TREATMENT, EARLY INTERVENTION |
| الوصف: | For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (<= 10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/26088952; info:eu-repo/semantics/altIdentifier/wos/WOS:000360937800003; volume:29; issue:9; firstpage:1823; lastpage:1831; numberofpages:9; journal:LEUKEMIA; http://hdl.handle.net/11586/142235Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84940757131 |
| DOI: | 10.1038/leu.2015.152 |
| الإتاحة: | https://doi.org/10.1038/leu.2015.152Test http://hdl.handle.net/11586/142235Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.42345B8E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/leu.2015.152 |
|---|